Exhibit 99.1

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Rule 3.19A.2

 

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

 

Introduced 30/9/2001.             Amended 01/01/11

 

 Name of Entity:  Radiopharm Theranostics Limited (ASX: RAD)
 ABN:  57 647 877 889

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

Name of Director:  Bruce Goodwin
  Date of Last Notice:  19 November 2025

 

Part 1 - Change of director’s relevant interests in securities

 

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or Indirect Interest Indirect  
     

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances giving rise to the relevant interest.

 Sundial Management Pty Limited of which Mr Goodwin is a Director and Shareholder.  
     
Date of change 17 September 2026
   
No. of securities held prior to change Nil
   
Class a. Fully Paid Ordinary Shares
  b. Listed Options
 
Number acquired a. 2,777,778 Fully Paid Ordinary Shares
  b. 2,777,778 Listed Options, EXP 31 Jul 29, EX $0.018
   
Number disposed Nil
           

Value/Consideration

Note:

If consideration is non-cash, provide details and estimated valuation

 a. $25,000 ($0.009 per Share)
b. Nil		  

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 1

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

 

No. of securities held after change     Shares Options  
    Indirect 2,777,778 2,777,778  
     

Nature of change

Example:
on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

 Acquisition of securities by way of participation in Securities Purchase Plan, following shareholder approval at the EGM held on 11 September 2026.

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract N/A
Nature of interest N/A

Name of registered holder

(if issued securities)

 N/A
Date of change N/A

No. and class of securities to which interest related prior to change

Note: Details are only required for a contract in relation to which the interest has changed

 N/A
Interest acquired N/A
Interest disposed N/A

Value/Consideration

Note: If consideration is non-cash, provide details and an estimated valuation

 N/A
Interest after change N/A

 

+ See chapter 19 for defined terms. 
  
Appendix 3Y Page 201/01/2011

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Part 3 – Closed period

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 3

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Rule 3.19A.2

 

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

 

Introduced 30/9/2001.             Amended 01/01/11

 

 Name of Entity:  Radiopharm Theranostics Limited (ASX: RAD)
 ABN:  57 647 877 889

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

Name of Director:  Ian Turner
  Date of Last Notice:  27 August 2026

 

Part 1 - Change of director’s relevant interests in securities

 

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or Indirect Interest Direct and indirect  
     

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances giving rise to the relevant interest.

 Superannuation fund  
     
Date of change 17 September 2026
           
No. of securities held prior to change     Shares Options  
    Direct 2,530,595 21,956,926  
    Indirect 7,454,697 70,422  
    Total 9,985,292 22,027,348
           
Class a. Fully Paid Ordinary Shares  
  b. Listed Options  
     
Number acquired Direct  
  a. 1,222,222 Fully Paid Ordinary Shares  
  b. 1,222,222 Listed Options, EXP 31 Jul 29, EX $0.018  
     
  Indirect  
  a. 1,555,556 Fully Paid Ordinary Shares  
  b. 1,555,556 Listed Options, EXP 31 Jul 29, EX $0.018  
     
Number disposed Nil  
           

Value/Consideration

Note:

If consideration is non-cash, provide details and estimated valuation

 a. $25,000 ($0.009 per Share)
b. Nil		  

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 1

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

 

No. of securities held after change     Shares Options  
    Direct 3,752,817 23,179,148  
    Indirect 9,010,253 1,625,978  
    Total 12,763,070 24,805,126
     

Nature of change

Example:
on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

 Acquisition of securities by way of participation in Securities Purchase Plan, following shareholder approval at the EGM held on 11 September 2026.

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract N/A
Nature of interest N/A

Name of registered holder

(if issued securities)

 N/A
Date of change N/A

No. and class of securities to which interest related prior to change

Note: Details are only required for a contract in relation to which the interest has changed

 N/A
Interest acquired N/A
Interest disposed N/A

Value/Consideration

Note: If consideration is non-cash, provide details and an estimated valuation

 N/A
Interest after change N/A

 

+ See chapter 19 for defined terms. 
  
Appendix 3Y Page 201/01/2011

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Part 3 – Closed period

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 3

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Rule 3.19A.2

 

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

 

Introduced 30/9/2001.             Amended 01/01/11

 

 Name of Entity:  Radiopharm Theranostics Limited (ASX: RAD)
 ABN:  57 647 877 889

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

  

Name of Director:  Paul Hopper
Date of Last Notice:  27 August 2026

 

Part 1 - Change of director’s relevant interests in securities

 

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or Indirect Interest Direct  
     

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances giving rise to the relevant interest.

 N/A  
     
Date of change 17 September 2026
           
No. of securities held prior to change     Shares Options  
    Direct 53,900,000 26,142,000  
    Indirect 93,821,428 9,017,518  
    Total 147,721,428 35,159,518  
           
Class   a. Fully Paid Ordinary Shares    
    b. Listed Options    
Number acquired   Indirect    
    a. 2,777,778 Fully Paid Ordinary Shares  
    b. 2,777,778 Listed Options, EXP 31 Jul 29, EX $0.018  
       
Number disposed     Nil      
           
Value/Consideration   a. $25,000 ($0.009 per Share)    

Note:

If consideration is non-cash, provide details and estimated valuation

   b. Nil     

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 1

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

 

No. of securities held after change     Shares Options  
    Direct 53,900,000 26,142,000  
    Indirect 96,599,206 11,795,296  
    Total 150,499,206 37,937,296
     

Nature of change

Example:
on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

 Acquisition of securities by way of participation in Securities Purchase Plan, following shareholder approval at the EGM held on 11 September 2026.

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract N/A
Nature of interest N/A

Name of registered holder

(if issued securities)

 N/A
Date of change N/A

No. and class of securities to which interest related prior to change

Note: Details are only required for a contract in relation to which the interest has changed

 N/A
Interest acquired N/A
Interest disposed N/A

Value/Consideration

Note: If consideration is non-cash, provide details and an estimated valuation

 N/A
Interest after change N/A

 

+ See chapter 19 for defined terms. 
  
Appendix 3Y Page 201/01/2011

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Part 3 – Closed period

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 3

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Rule 3.19A.2

 

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

 

Introduced 30/9/2001.             Amended 01/01/11

 

 Name of Entity:  Radiopharm Theranostics Limited (ASX: RAD)
 ABN:  57 647 877 889

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

Name of Director:  Riccardo Canevari
  Date of Last Notice:  27 August 2026

 

Part 1 - Change of director’s relevant interests in securities

 

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or Indirect Interest Direct  
     

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances giving rise to the relevant interest.

 N/A  
     
Date of change 17 September 2026
           
No. of securities held prior to change     Shares Options  
    Direct 20,029,986 183,412,299  
    Indirect 2,650,000 -  
    Total 22,679,986 183,412,299
           
Class a. Fully Paid Ordinary Shares  
  b. Listed Options  
     
Number acquired  a. 3,888,889 Fully Paid Ordinary Shares  
b. 3,888,889 Listed Options, EXP 31 Jul 29, EX $0.018  
     
Number disposed Nil  
           

Value/Consideration

Note:

If consideration is non-cash, provide details and estimated valuation

 a. $35,000 ($0.009 per Share)
b. Nil		  

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 1

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

 

No. of securities held after change     Shares Options  
    Direct 23,918,875 187,301,188  
    Indirect 2,650,000 -  
    Total 26,568,875 187,301,188 
     

Nature of change

Example:
on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

 Acquisition of securities by way of participation in Securities Purchase Plan, following shareholder approval at the EGM held on 11 September 2026

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract N/A
Nature of interest N/A

Name of registered holder

(if issued securities)

 N/A
Date of change N/A

No. and class of securities to which interest related prior to change

Note: Details are only required for a contract in relation to which the interest has changed

 N/A
Interest acquired N/A
Interest disposed N/A

Value/Consideration

Note: If consideration is non-cash, provide details and an estimated valuation

 N/A
Interest after change N/A

 

+ See chapter 19 for defined terms. 
  
Appendix 3Y Page 201/01/2011

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Part 3 – Closed period

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided, on what date was this provided? N/A

 

+ See chapter 19 for defined terms. 
  
01/01/2011Appendix 3Y Page 3